BioLeap

BioLeap is an emerging drug research and development company supported by next-generation computational fragment-based design technology. BioLeap's design platform can rapidly predict binding affinity based on thermodynamic principles, providing drug designers with new insights to effectively create non-obvious molecules and improve existing ones. BioLeap's technology offers a viable alternative to high-throughput screening and traditional shape-based "drilling." On October 22, 2016, BioLeap, LLC was acquired by MetaLeaps, LLC.